Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02763410
Other study ID # RC15_0420
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 8, 2016
Est. completion date March 23, 2022

Study information

Verified date March 2024
Source Nantes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Safety during transfusions is a major issue in medical economics. Despite drastic quality control measures, transfusion is still a source of short, mid and long-term morbi-mortality. This can be explained to some extent by changes in the composition of the packed red blood cell (PRBC) supernatant during storage essentially with the appearance of immunologically active compounds possibly involved in organ dysfunction on the one hand and post-transfusion immunomodulation on the other hand. These phenomena impact upon outcomes for cardiac surgery patients. In terms of organ dysfunction, kidney failure due to acute tubular necrosis and pulmonary failure are the 2 main issues. Following cardiac surgery, 11% of patients will present with transient renal dysfunction characterised by a 25% increase in serum creatinine levels and 3.5% require dialysis. The intensity of acute renal failure (ARF) is correlated to resuscitation : a 20% increase in serum creatinine levels 2 to 3 days after surgery significantly raises morbidity rates and a 50% increase raises the mortality rate to 10%. The precise mechanisms governing post-transfusion immunomodulation have not yet to be defined. The appearance of soluble type I Human leukocytes Antigen (HLA) molecules (sHLA-I), the FAS ligand (FAS-L) or cluster designation 40 (CD40-L) in the supernatant of PRBCs along the storage of blood products may be involved in such phenomena. These molecules are capable of activating or triggering the death of innate or adaptive immunity cells, especially the Natural Killer (NK) cells. Consequently the investigators propose to focus specifically on the detailed composition of transfused PRBC supernatants in order to identify the candidate molecules responsible for organ dysfunction or post-transfusion immunoparalysis. The investigators will combine a clinical approach based on the transcriptional analysis of renal tubular cells in transfused patients and an ex-vivo approach investigating the effect of the supernatant on immune cells and the Natural Killer cells of healthy volunteers


Recruitment information / eligibility

Status Completed
Enrollment 199
Est. completion date March 23, 2022
Est. primary completion date March 23, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Non-emergency cardiac surgery under extracorporeal circulation (CEC) with cardioplegia: And no indication of pre-surgical PRBC transfusion (priming excluded), And no indication of transfusion with fresh frozen plasma or pre-surgical platelet concentrate Exclusion Criteria: - Heart and/or lung transplant surgery; - Emergency surgery to be performed within 24 hours; - Patient <18 years old; - Pregnant woman - Protected adult - Adult incapable of expressing his/her non-opposition - Opposition expressed by the patient on recording his/her data; - No French social security; - Patient who underwent a transfusion in the 3 months prior to surgery; - Surgery due to endocarditis or suspected endocarditis; - Myocardial infarction < 15 days; - Patient receiving inotropic or vasopressor prior to surgery; - Patient receiving immunosuppressant treatment; - Patient receiving corticosteroids for 21 days or more; - Seropositive patient known to be suffering from HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) - Currently taking antibiotics (except permitted peri-surgical antibiotic prophylaxis ); - History of advancing cancer; - Clearance < 40 ml/min/m2 according to the Modification of Diet in Renal Disease (MDRD) during the pre-surgical assessment; - Positive irregular antibody test warranting a cross-match prior to transfusion. - Patients with indwelling urinary catheter preoperatively - preoperative positive urine culture - Urinary tract infection <21 days before surgery - Background gesture on the upper or lower urinary tract Exclusion criteria analysis - In the renal insufficient group: Patient transfused plasma (s) Fresh Frozen (s) (PFCs) or concentrate (s) platelet (s) (CP) after the balance sheet T6 (6 hours after arrival in the ICU) and before the diagnosis of ARF, - strict anuric patient not to achieve a 50 ml urine sample at least - Reversal surgery requiring CEC before the 48th hour - Surgical Complication could explain the acute renal failure (IRA)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
PRBC transfusion


Locations

Country Name City State
France CHU de Nantes Nantes

Sponsors (2)

Lead Sponsor Collaborator
Nantes University Hospital Etablissement Français du Sang

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary link between the composition of the PRBC supernatant and the onset of renal failure 48 hours following surgery
Secondary Respiratory dysfunction in the ICU defined by a blood pressure of oxygen (PaO2)/inspired oxygen fraction (FiO2) ratio < 300 on at least one occasion within 28 days
Secondary Number of dialysis days within 28 days
Secondary Duration of stay within 28 days
Secondary Ventilation period (in hours); within 28 days
Secondary ICU-acquired infection within 28 days
Secondary Status at discharge from ICU: Dead/alive day 28
Secondary Study of transfusion-related accidents recorded in ICU within 28 days
Secondary Hospital admission, regardless of cause 1 year
Secondary Hospital admission due to infection 1 year
Secondary Diagnosis of cancer 1 year
Secondary Clinical course of pre-existing cancer 1 year
Secondary Survival 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT04084301 - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury N/A
Completed NCT03292029 - Pilot Medical Evaluation of the T50 Test N/A
Suspended NCT04589065 - SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device) N/A
Completed NCT03806998 - Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure Phase 3
Active, not recruiting NCT03672110 - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen Phase 3
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT02116270 - Accelerated Immunosenescence and Chronic Kidney Disease N/A
Completed NCT01388270 - Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis Phase 4
Completed NCT01859273 - Adherence Enhancement for Renal Transplant Patients N/A
Completed NCT01187953 - Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacroâ„¢ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx Phase 3
Completed NCT00966615 - The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition Phase 4
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01008631 - The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers N/A
Completed NCT00765661 - Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients Phase 2
Completed NCT00737672 - GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis Phase 3
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Recruiting NCT00470769 - The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR N/A
Terminated NCT00338455 - Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC Phase 2
Completed NCT03917186 - Desflurane vs. Sevoflurane in Endovascular Aortic Repair Phase 4